CD8A and neoplasm: Increases in intratumoral anti-tumor immune cells and IFNγ were found to imbue CD8+ T cells with lytic activity against tumor cells, and the addition of IL-12 as immunotherapy can augment this RT-induced anti-tumor immunity [94,98].